This study conducted using the Corrona Rheumatoid Arthritis (RA) registry dataset demonstrated that tocilizumab monotherapy improved disease activity as effectively as tumor necrosis factor inhibitors (TNFis) plus any dose of methotrexate (MTX) in patients with prior TNFi exposure in routine clinical practice, suggesting that it is an effective alternate treatment option for patients who cannot tolerate or prefer not to use MTX.
Results of this post-hoc analysis of the TARGET study demonstrated that patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor (TNF) inhibitors treated with sarilumab 150 mg or 200 mg every 2 weeks on a conventional synthetic disease-modifying antirheumatic drug (csDMARD) background achieved greater clinical responses compared with those treated with placebo, regardless of baseline disease activity. However, a greater sarilumab treatment effect was achieved by patients with higher baseline disease activity.
In this analysis of the TARGET study, a sustained clinically significant response was achieved by more patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response to, or intolerance of, tumor necrosis factor (TNF) inhibitors treated with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) versus those treated with placebo plus csDMARDs.
This post-hoc analysis showed that the efficacy of sarilumab was maintained or improved in patients with rheumatoid arthritis (RA) who switched or continued into the open-label EXTEND trial to receive sarilumab 200 mg every 2 weeks (q2w) after completion of the ASCERTAIN trial, with particularly increased efficacy occurring in those who initially received tocilizumab or sarilumab 150 mg q2w